What condition is Valsartan/Sacubitril (Entresto) indicated for?

Valsartan/Sacubitril, marketed under the brand name Entresto, is specifically indicated for the treatment of heart failure with reduced ejection fraction (HFrEF). This combination medication combines an angiotensin receptor blocker (valsartan) and a neprilysin inhibitor (sacubitril), which work synergistically to enhance vasodilation, decrease cardiac workload, and reduce the risk of heart failure hospitalization and cardiovascular death.

The efficacy of Entresto in patients with HFrEF has been demonstrated in clinical studies, leading to its approval for this specific condition. It is important to differentiate this from heart failure with preserved ejection fraction (HFpEF), where the underlying mechanisms and therapeutic objectives differ. Furthermore, while Entresto can help manage blood pressure due to its vasodilatory effects, its primary indication is specifically tailored for heart failure with reduced ejection fraction, highlighting its role in managing the complexities of this condition.